Inactive

This acquisition will allow BARDA to invest Project Bioshield funds for late-stage clinical development, regulatory approval for 2-PAM autoinjectors (as a drug/device combination product) to treat org... This acquisition will allow BARDA to invest Project Bioshield funds for late-stage clinical development, regulatory approval for 2-PAM autoinjectors (as a drug/device combination product) to treat organophosphate (OP) poisoning, including nerve agents, in adult and pediatric populations, and procurement of 2-PAM autoinjectors for the SNS/CHEMPACK Program. Questions are due on July 21, 2022. Proposals are due on August 15, 2022. Attached to this SAM Notice are the following: 1. Request for Proposals (Solicitation) 2. SF33 3. Budget Template Spreadsheet